Mount Sinai Dermatologists Show Promising Results Using Combination Therapy for Vitiligo Patients
Adding light therapy to ritlecitinib treatment improves facial and total skin repigmentation in patients with nonsegmental vitiligo
The combination of a targeted oral medication with light therapy may enhance repigmentation for patients living with nonsegmental vitiligo, a team of researchers led by Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, reports.
The study, published in the April issue of Journal of the American Academy of Dermatology, evaluated the efficacy and safety of ritlecitinib—an oral JAK3/TEC family kinase inhibitor—alone and in combination with narrow-band ultraviolet B (nbUVB) phototherapy at inducing recovery of skin color in areas that had lost it.
In a 24-week extension of a phase 2b clinical trial, the Mount Sinai researchers found that patients receiving ritlecitinib with nbUVB phototherapy experienced greater improvements in vitiligo severity compared to those receiving ritlecitinib alone. Notably, the combination led to a mean 69.6 percent improvement in facial repigmentation, compared to 55.1 percent with ritlecitinib alone. Total body repigmentation also improved more significantly with the combination therapy.
Vitiligo is a chronic autoimmune skin condition characterized by the loss of pigment-producing cells, leading to patchy depigmentation. According to the National Institute of Health, it affects approximately one to two percent of the global population and often carries significant psychological and social burdens.
“These results are encouraging and suggest that this combination may provide added benefit for patients with vitiligo,” said Dr. Guttman-Yassky. “Our findings underscore the potential of precision therapies, including targeted oral treatments, to be safely integrated with traditional modalities like light therapy to enhance patient outcomes.”
While the study had limitations—including a relatively small sample size of 230 (187 patients that received ritlecitinib monotherapy and 43 that received ritlecitinib plus nbUVB) and an exploratory design—the findings lay important groundwork for future studies and therapeutic strategies.
“These findings represent another step forward in our mission to offer hope and improved quality of life to people living with vitiligo and other dermatologic conditions,” said Dr. Guttman-Yassky.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, employing 48,000 people across its hospitals and more than 400 outpatient practices, as well as more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
